Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease

Changsu Han, Dong Suk Shim, Soo Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi Un Pae

Research output: Contribution to journalReview article

Abstract

Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation for the treatment of such medical conditions. Beyond symptomatic effects on such neuropsychiatric conditions, it has also been proposed to hold some neurotoxicity effects, including reversible brain atrophy (which may be a serious complication associated with substantial cognitive decline), although it has shown neuroprotective effects. Common adverse events include sedation, tiredness and gastrointestinal symptoms. According to a recent study, divalproex treatment was associated with accelerated brain volume loss over 1 year, which could possibly lead to greater cognitive impairment. Hence, this article will discuss clinical and further research implications of this study, as well as the potential limitations and significance of the research.

Original languageEnglish
Pages (from-to)155-158
Number of pages4
JournalExpert Review of Neurotherapeutics
Volume12
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Valproic Acid
Atrophy
Alzheimer Disease
Brain
Neuroprotective Agents
Bipolar Disorder
Research
Anticonvulsants
Schizophrenia
Seizures
Sodium
Cognitive Dysfunction

Keywords

  • adverse event
  • atrophy
  • cognitive decline
  • divalproex sodium

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. / Han, Changsu; Shim, Dong Suk; Lee, Soo Jung; Patkar, Ashwin A.; Masand, Prakash S.; Pae, Chi Un.

In: Expert Review of Neurotherapeutics, Vol. 12, No. 2, 01.02.2012, p. 155-158.

Research output: Contribution to journalReview article

Han, Changsu ; Shim, Dong Suk ; Lee, Soo Jung ; Patkar, Ashwin A. ; Masand, Prakash S. ; Pae, Chi Un. / Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease. In: Expert Review of Neurotherapeutics. 2012 ; Vol. 12, No. 2. pp. 155-158.
@article{f5d019e0ccfb405f9e64cec5baa658b8,
title = "Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease",
abstract = "Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation for the treatment of such medical conditions. Beyond symptomatic effects on such neuropsychiatric conditions, it has also been proposed to hold some neurotoxicity effects, including reversible brain atrophy (which may be a serious complication associated with substantial cognitive decline), although it has shown neuroprotective effects. Common adverse events include sedation, tiredness and gastrointestinal symptoms. According to a recent study, divalproex treatment was associated with accelerated brain volume loss over 1 year, which could possibly lead to greater cognitive impairment. Hence, this article will discuss clinical and further research implications of this study, as well as the potential limitations and significance of the research.",
keywords = "adverse event, atrophy, cognitive decline, divalproex sodium",
author = "Changsu Han and Shim, {Dong Suk} and Lee, {Soo Jung} and Patkar, {Ashwin A.} and Masand, {Prakash S.} and Pae, {Chi Un}",
year = "2012",
month = "2",
day = "1",
doi = "10.1586/ern.11.194",
language = "English",
volume = "12",
pages = "155--158",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Association of chronic divalproex sodium use and brain atrophy in Alzheimer's disease

AU - Han, Changsu

AU - Shim, Dong Suk

AU - Lee, Soo Jung

AU - Patkar, Ashwin A.

AU - Masand, Prakash S.

AU - Pae, Chi Un

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation for the treatment of such medical conditions. Beyond symptomatic effects on such neuropsychiatric conditions, it has also been proposed to hold some neurotoxicity effects, including reversible brain atrophy (which may be a serious complication associated with substantial cognitive decline), although it has shown neuroprotective effects. Common adverse events include sedation, tiredness and gastrointestinal symptoms. According to a recent study, divalproex treatment was associated with accelerated brain volume loss over 1 year, which could possibly lead to greater cognitive impairment. Hence, this article will discuss clinical and further research implications of this study, as well as the potential limitations and significance of the research.

AB - Divalproex sodium has been widely use for the treatment of bipolar disorder, behavioral control in schizophrenia, seizure and agitation in Alzheimer's disease. With the advent of other mood stabilizers and anticonvulsants, the use of divaplroex sodium has been slightly decreased; however, it has been a major mediation for the treatment of such medical conditions. Beyond symptomatic effects on such neuropsychiatric conditions, it has also been proposed to hold some neurotoxicity effects, including reversible brain atrophy (which may be a serious complication associated with substantial cognitive decline), although it has shown neuroprotective effects. Common adverse events include sedation, tiredness and gastrointestinal symptoms. According to a recent study, divalproex treatment was associated with accelerated brain volume loss over 1 year, which could possibly lead to greater cognitive impairment. Hence, this article will discuss clinical and further research implications of this study, as well as the potential limitations and significance of the research.

KW - adverse event

KW - atrophy

KW - cognitive decline

KW - divalproex sodium

UR - http://www.scopus.com/inward/record.url?scp=84863061513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863061513&partnerID=8YFLogxK

U2 - 10.1586/ern.11.194

DO - 10.1586/ern.11.194

M3 - Review article

C2 - 22288670

AN - SCOPUS:84863061513

VL - 12

SP - 155

EP - 158

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 2

ER -